UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

The American heart journal, 2010-10, Vol.160 (4), p.635-641.e2

2010

Volltextzugriff (PDF)

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet (British edition), 2015-06, Vol.385 (9984), p.2288-2295

2015

Volltextzugriff (PDF)

Mortality in Patients With Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial

The American journal of medicine, 2016-08, Vol.129 (8), p.850-857.e2

2016

Volltextzugriff (PDF)

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Journal of cardiovascular pharmacology, 2013-08, Vol.62 (2), p.212-221

2013

Volltextzugriff (PDF)

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

British journal of clinical pharmacology, 2016-12, Vol.82 (6), p.1591-1600

2016

Volltextzugriff (PDF)

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin

British journal of clinical pharmacology, 2013-04, Vol.75 (4), p.966-978

2013

Volltextzugriff (PDF)

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48

European journal of heart failure, 2016-09, Vol.18 (9), p.1153-1161

2016

Volltextzugriff (PDF)

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Hypertension (Dallas, Tex. 1979), 2019-09, Vol.74 (3), p.597-605

2019

Volltextzugriff (PDF)

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination

Journal of cardiovascular pharmacology, 2012-10, Vol.60 (4), p.335

2012

Volltextzugriff (PDF)

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

Journal of cardiovascular pharmacology, 2012-10, Vol.60 (4), p.335-341

2012

Volltextzugriff (PDF)

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Journal of thrombosis and haemostasis, 2023-10, Vol.21 (10), p.2929-2940

2023

Volltextzugriff (PDF)

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

Journal of thrombosis and haemostasis, 2021-11, Vol.19 (11), p.2801-2813

2021

Volltextzugriff (PDF)

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban

Thrombosis research, 2015-10, Vol.136 (4), p.825-831

2015

Volltextzugriff (PDF)

THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN

Journal of the American College of Cardiology, 2014-04, Vol.63 (12), p.A2095-A2095

2014

Volltextzugriff (PDF)

Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Stroke (1970), 2014-08, Vol.45 (8), p.2372-2378

2014

Volltextzugriff (PDF)

RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL

Journal of the American College of Cardiology, 2014-04, Vol.63 (12), p.A329-A329

2014

Volltextzugriff (PDF)

DRUG-DRUG INTERACTION STUDIES OF CARDIOVASCULAR DRUGS (AMIODARONE, DIGOXIN, QUINIDINE, ATORVASTATIN AND VERAPAMIL) INVOLVING P-GLYCOPROTEIN (P-GP), AN EFFLUX TRANSPORTER, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E1510-E1510

2011

Volltextzugriff (PDF)

Cerebrovascular Events in 21105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Stroke (1970), 2014, Vol.45 (8), p.2372-2378

2014

Volltextzugriff (PDF)

CARDIAC STRUCTURE AND FUNCTION AND CHADS2 RISK SCORE IN PATIENTS WITH ATRIAL FIBRILLATION: THE EFFECTS ANTICOAGULATION WITH FACTOR XA NEXT GENERATION IN AFTHROMBOLYSIS IN MYOCARDIAL INFARCTION 48 (ENGAGE AF -TIMI 48) ECHOCARDIOGRAPHIC STUDY

Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E964-E964

2013

Volltextzugriff (PDF)

An Analysis of Paediatric CD4 Counts for Acquired Immune Deficiency Syndrome Using Flexible Random Curves

Applied Statistics, 1996-01, Vol.45 (2), p.151-163

1996

Volltextzugriff (PDF)

Characterization of pre- and post-failure displacements of the Huangnibazi landslide in Li County with multi-source satellite observations

Engineering geology, 2019-07, Vol.257, p.105140, Article 105140

2019

Volltextzugriff (PDF)

A Fitting Method to Characterize the Gaseous Venting Behavior of Lithium–Ion Batteries in a Sealed Chamber during Thermal Runaway

Energies (Basel), 2023-12, Vol.16 (23), p.7874

2023

Volltextzugriff (PDF)

Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors

Frontiers in immunology, 2023, Vol.14, p.1308264-1308264

2023

Volltextzugriff (PDF)

Long non-coding RNA Homeobox D gene cluster antisense growth-associated long noncoding RNA/microRNA-182-5p/Homeobox protein A10 alleviates postmenopausal osteoporosis via accelerating osteoblast differentiation of bone marrow mesenchymal stem cells

Journal of orthopaedic surgery and research, 2023-09, Vol.18 (1), p.1-726, Article 726

2023

Volltextzugriff (PDF)

Imbalance between Glutamate and GABA in Fmr1 Knockout Astrocytes Influences Neuronal Development

Genes, 2016-08, Vol.7 (8), p.45-45

2016

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

KollektionThieme - Connect here FIRST to enable access

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Englisch
(25)
Chinesisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Mortality in Patients With Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban

THE IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE ON THE ANTICOAGULATORY EFFECTS OF EDOXABAN

Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL

DRUG-DRUG INTERACTION STUDIES OF CARDIOVASCULAR DRUGS (AMIODARONE, DIGOXIN, QUINIDINE, ATORVASTATIN AND VERAPAMIL) INVOLVING P-GLYCOPROTEIN (P-GP), AN EFFLUX TRANSPORTER, ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR

Cerebrovascular Events in 21105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

CARDIAC STRUCTURE AND FUNCTION AND CHADS2 RISK SCORE IN PATIENTS WITH ATRIAL FIBRILLATION: THE EFFECTS ANTICOAGULATION WITH FACTOR XA NEXT GENERATION IN AFTHROMBOLYSIS IN MYOCARDIAL INFARCTION 48 (ENGAGE AF -TIMI 48) ECHOCARDIOGRAPHIC STUDY

An Analysis of Paediatric CD4 Counts for Acquired Immune Deficiency Syndrome Using Flexible Random Curves

Characterization of pre- and post-failure displacements of the Huangnibazi landslide in Li County with multi-source satellite observations

A Fitting Method to Characterize the Gaseous Venting Behavior of Lithium–Ion Batteries in a Sealed Chamber during Thermal Runaway

Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors

Long non-coding RNA Homeobox D gene cluster antisense growth-associated long noncoding RNA/microRNA-182-5p/Homeobox protein A10 alleviates postmenopausal osteoporosis via accelerating osteoblast differentiation of bone marrow mesenchymal stem cells

Imbalance between Glutamate and GABA in Fmr1 Knockout Astrocytes Influences Neuronal Development

Aktive Filter

Suchergebnisse filtern